<DOC>
	<DOC>NCT01168414</DOC>
	<brief_summary>This is a single-center, cross-over comparison parallel group randomized trial designed to evaluate the efficacy and safety of Ganfort compared to Duotrav for a treatment period of 8 weeks each.</brief_summary>
	<brief_title>A Study of Ganfort Versus Duotrav in Patients With Primary Open Angle Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Cloprostenol</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>1. Visual acuity 6/60 or better 2. Patients who are controlled (IOP &lt; 21 mmHg) on nonfixed combination of Latanoprost &amp; Timolol for at least 3 months before the baseline visit and 3. Patients on monotherapy either Latanoprost or Timolol who are eligible for dual therapy being not satisfactorily controlled (IOP&gt;21mmHG) 1. Angle closure glaucoma 2. Neovascular Galucoma 3. Secondary open angle glaucoma 4. Ocular infection/inflammation within 3 months 5. Ocular surgery within 3 months 6. History of Refractive surgery 7. Argon laser trabeculoplasty/Selective laser trabeculoplasty 8. Pregnancy/nursing 9. Hypersensitivity to benzalkonium chloride or to any other components of the trial drugs solution. 10. Patients in whom betablockers are contraindicated 11. Patients on any drugs known to affect IOP.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>